AHA slides: Rivaroxaban users more likely to stay on therapy

Candace Stuart | November 20, 2013 | Cardiovascular Business | Heart Rhythm

Researchers reported Nov. 19 at the American Heart Association scientific session in Dallas that at three months 85 percent of patients with nonvalvular atrial fibrillation treated with rivaroxaban had continued to take the anticoagulant compared with 76 percent of patients on warfarin.

The real-world study was designed to compare the effectiveness, safety and persistence in use of rivaroxaban (Xarelto, Janssen Pharmaceuticals/Bayer HealthCare) and warfarin in patients with atrial fibrillation who are at risk of stroke and systemic embolism. The study found no significant difference in effectiveness and safety and showed the risk of treatment discontinuation was lower for rivaroxaban.

Winnie W. Nelson of Janssen presented the findings. Janssen funded the study.

Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final from Trimed Media Group

Candace Stuart, Contributor

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

AHA slides: Rivaroxaban users more likely to stay on therapy

Related Content

Around the web